Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Novel Trifluoromethylated Enobosarm Analogues with Potent Anti-androgenic Activity in vitro and Tissue Selectivity in vivo.

Dart DA, Kandil S, Tommasini-Ghelfi S, Serrano de Almeida G, Bevan CL, Jiang W, Westwell AD.

Mol Cancer Ther. 2018 Jun 12. pii: molcanther.0037.2018. doi: 10.1158/1535-7163.MCT-18-0037. [Epub ahead of print]

PMID:
29895558
2.

Light-triggered enzymatic reactions in nested vesicle reactors.

Hindley JW, Elani Y, McGilvery CM, Ali S, Bevan CL, Law RV, Ces O.

Nat Commun. 2018 Mar 15;9(1):1093. doi: 10.1038/s41467-018-03491-7.

3.

Lipid profiling of complex biological mixtures by liquid chromatography/mass spectrometry using a novel scanning quadrupole data-independent acquisition strategy.

Gethings LA, Richardson K, Wildgoose J, Lennon S, Jarvis S, Bevan CL, Vissers JPC, Langridge JI.

Rapid Commun Mass Spectrom. 2017 Oct 15;31(19):1599-1606. doi: 10.1002/rcm.7941.

PMID:
28703389
4.

The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells.

Koushyar S, Economides G, Zaat S, Jiang W, Bevan CL, Dart DA.

Oncogenesis. 2017 May 15;6(5):e333. doi: 10.1038/oncsis.2017.32.

5.

A novel role for GSK3β as a modulator of Drosha microprocessor activity and MicroRNA biogenesis.

Fletcher CE, Godfrey JD, Shibakawa A, Bushell M, Bevan CL.

Nucleic Acids Res. 2016 Oct 23. pii: gkw938. [Epub ahead of print]

6.

WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer.

Leach DA, Powell SM, Bevan CL.

Endocr Relat Cancer. 2016 Nov;23(11):T85-T108. Epub 2016 Sep 19. Review.

7.

WOMEN IN CANCER PROFILE: A gender agenda?

Bevan CL.

Endocr Relat Cancer. 2016 Nov;23(11):P5-P8. Epub 2016 Sep 6. No abstract available.

8.

Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis.

Metcalf GA, Shibakawa A, Patel H, Sita-Lumsden A, Zivi A, Rama N, Bevan CL, Ladame S.

Anal Chem. 2016 Aug 16;88(16):8091-8. doi: 10.1021/acs.analchem.6b01594. Epub 2016 Aug 7.

9.

Advances in genetics: widening our understanding of prostate cancer.

Pine AC, Fioretti FF, Brooke GN, Bevan CL.

F1000Res. 2016 Jun 27;5. pii: F1000 Faculty Rev-1512. doi: 10.12688/f1000research.8019.1. eCollection 2016. Review.

10.

In Vivo Imaging of Nuclear Receptor Transcriptional Activity.

Dart DA, Bevan CL.

Methods Mol Biol. 2016;1443:203-17. doi: 10.1007/978-1-4939-3724-0_13.

PMID:
27246342
11.

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL.

Mol Cell Proteomics. 2015 May;14(5):1201-16. doi: 10.1074/mcp.M113.036764. Epub 2015 Feb 18.

12.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

13.

Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers.

Fletcher CE, Dart DA, Bevan CL.

Endocr Relat Cancer. 2014 Oct;21(5):R409-29. doi: 10.1530/ERC-14-0208. Epub 2014 Jul 25. Review.

14.

Revising the role of the androgen receptor in breast cancer.

Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN.

J Mol Endocrinol. 2014 Jun;52(3):R257-65. doi: 10.1530/JME-14-0030. Epub 2014 Apr 16. Review.

PMID:
24740738
15.

Engineered repressors are potent inhibitors of androgen receptor activity.

Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL.

Oncotarget. 2014 Feb 28;5(4):959-69.

16.

Circulating nucleic acids as biomarkers of prostate cancer.

Sita-Lumsden A, Fletcher CE, Dart DA, Brooke GN, Waxman J, Bevan CL.

Biomark Med. 2013 Dec;7(6):867-77. doi: 10.2217/bmm.13.104. Review.

PMID:
24266819
17.

Visualising androgen receptor activity in male and female mice.

Dart DA, Waxman J, Aboagye EO, Bevan CL.

PLoS One. 2013 Aug 7;8(8):e71694. doi: 10.1371/journal.pone.0071694. Print 2013.

18.

Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer.

Frampton AE, Fletcher CE, Gall TM, Castellano L, Bevan CL, Stebbing J, Krell J.

Expert Rev Mol Diagn. 2013 Jun;13(5):425-30. doi: 10.1586/erm.13.31.

PMID:
23782250
19.

Circulating microRNAs as potential new biomarkers for prostate cancer.

Sita-Lumsden A, Dart DA, Waxman J, Bevan CL.

Br J Cancer. 2013 May 28;108(10):1925-30. doi: 10.1038/bjc.2013.192. Epub 2013 Apr 30. Review.

20.

Mini-review: Foldosome regulation of androgen receptor action in prostate cancer.

Cano LQ, Lavery DN, Bevan CL.

Mol Cell Endocrinol. 2013 Apr 30;369(1-2):52-62. doi: 10.1016/j.mce.2013.01.023. Epub 2013 Feb 8. Review.

PMID:
23395916
21.

Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.

Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL.

Mol Endocrinol. 2012 Oct;26(10):1694-706. Epub 2012 Aug 16.

22.

Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer.

Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL.

Hum Mol Genet. 2012 Jul 15;21(14):3112-27. doi: 10.1093/hmg/dds139. Epub 2012 Apr 14.

23.

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.

Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL.

Oncogene. 2012 Oct 25;31(43):4588-98. doi: 10.1038/onc.2011.591. Epub 2011 Dec 19.

24.

Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors.

Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B, Bevan CL.

J Biol Chem. 2011 May 20;286(20):17796-808. doi: 10.1074/jbc.M110.198655. Epub 2011 Mar 17.

25.

Androgen receptor signalling in prostate cancer: the functional consequences of acetylation.

Lavery DN, Bevan CL.

J Biomed Biotechnol. 2011;2011:862125. doi: 10.1155/2011/862125. Epub 2010 Dec 28.

26.

FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.

Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL.

Cancer Res. 2011 Feb 1;71(3):914-24. doi: 10.1158/0008-5472.CAN-10-0874. Epub 2010 Dec 17.

27.

Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.

Reebye V, Bevan CL, Nohadani M, Hajitou A, Habib NA, Mintz PJ.

Cell Signal. 2010 Dec;22(12):1874-81. doi: 10.1016/j.cellsig.2010.07.015. Epub 2010 Aug 2.

PMID:
20688158
28.

Metabolic signatures of malignant progression in prostate epithelial cells.

Teahan O, Bevan CL, Waxman J, Keun HC.

Int J Biochem Cell Biol. 2011 Jul;43(7):1002-9. doi: 10.1016/j.biocel.2010.07.003. Epub 2010 Jul 13.

PMID:
20633696
29.

HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions.

Villaronga MA, Lavery DN, Bevan CL, Llanos S, Belandia B.

Oncogene. 2010 Jan 21;29(3):411-20. doi: 10.1038/onc.2009.309. Epub 2009 Oct 5.

30.

The role of androgen receptor mutations in prostate cancer progression.

Brooke GN, Bevan CL.

Curr Genomics. 2009 Mar;10(1):18-25. doi: 10.2174/138920209787581307.

31.

Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL.

Endocr Relat Cancer. 2009 Dec;16(4):1157-69. doi: 10.1677/ERC-09-0028. Epub 2009 Jul 27.

32.

Notch signaling: a potential therapeutic target in prostate cancer.

Villaronga MA, Bevan CL, Belandia B.

Curr Cancer Drug Targets. 2008 Nov;8(7):566-80. Review.

33.
34.

Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells.

Chang GT, Gamble SC, Jhamai M, Wait R, Bevan CL, Brinkmann AO.

Biochim Biophys Acta. 2007 May;1774(5):575-82. Epub 2007 Mar 24.

PMID:
17467349
35.

Mechanisms of androgen receptor repression in prostate cancer.

Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D, Dart DA, Belandia B, Bevan CL.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1124-7.

36.

Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.

Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL.

Oncogene. 2007 Mar 15;26(12):1757-68. Epub 2006 Sep 11.

PMID:
16964284
37.

The endocrine-disrupting compound, nonylphenol, inhibits neurotrophin-dependent neurite outgrowth.

Bevan CL, Porter DM, Schumann CR, Bryleva EY, Hendershot TJ, Liu H, Howard MJ, Henderson LP.

Endocrinology. 2006 Sep;147(9):4192-204. Epub 2006 Jun 15.

PMID:
16777973
38.

Androgen receptor in prostate cancer: cause or cure?

Bevan CL.

Trends Endocrinol Metab. 2005 Nov;16(9):395-7. Epub 2005 Oct 3.

PMID:
16202619
39.

Hey1, a mediator of notch signaling, is an androgen receptor corepressor.

Belandia B, Powell SM, García-Pedrero JM, Walker MM, Bevan CL, Parker MG.

Mol Cell Biol. 2005 Feb;25(4):1425-36.

40.

Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.

Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC, Bevan CL.

Clin Cancer Res. 2004 Nov 1;10(21):7392-401.

41.

Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.

Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL.

Endocr Relat Cancer. 2004 Mar;11(1):117-30.

42.

Androgens target prohibitin to regulate proliferation of prostate cancer cells.

Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, Lam EW, Bevan CL.

Oncogene. 2004 Apr 15;23(17):2996-3004.

PMID:
14968116
43.

Environmental estrogens alter early development in Xenopus laevis.

Bevan CL, Porter DM, Prasad A, Howard MJ, Henderson LP.

Environ Health Perspect. 2003 Apr;111(4):488-96.

44.

Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control.

Christiaens V, Bevan CL, Callewaert L, Haelens A, Verrijdt G, Rombauts W, Claessens F.

J Biol Chem. 2002 Dec 20;277(51):49230-7. Epub 2002 Oct 4.

45.

The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1.

Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG.

Mol Cell Biol. 1999 Dec;19(12):8383-92.

46.

Phenotypic diversity in siblings with partial androgen insensitivity syndrome.

Evans BA, Hughes IA, Bevan CL, Patterson MN, Gregory JW.

Arch Dis Child. 1997 Jun;76(6):529-31. Review.

47.

Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome.

Bevan CL, Hughes IA, Patterson MN.

J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):19-26.

PMID:
9328206
48.

Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome.

Bevan CL, Brown BB, Davies HR, Evans BA, Hughes IA, Patterson MN.

Hum Mol Genet. 1996 Feb;5(2):265-73.

PMID:
8824883

Supplemental Content

Loading ...
Support Center